



9/22/04

1646

Jfw

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Meade et al.

Serial No.: 09/849,657

Art Unit: 1646

Filed: 05/04/2001

Examiner:

For: Transgenically Produced Decorin

Atty. Docket No.: GTC-21

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

The citations listed on the attached Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56,

**CERTIFICATE OF MAILING BY EXPRESS MAIL**

I hereby certify that under 37 CFR §1.10 that this correspondence is being deposited on September 21, 2004 with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Kristin Kaberry

§1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

A copy of the PCT International Search Report from a counterpart application is enclosed. Legible copies of all items listed in Form PTO-1449 accompany this information statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

I hereby certify that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. 37 CFR 1.97 (e) (1).

It is Applicant's understanding that no fee is due; however, if the Applicant is incorrect, please charge any necessary fees for the above-captioned application to Deposit Account No. 502092.

The person making this statement is the attorney who signs below on the basis of the information in the attorney's file.

Date:

9/20/04

Respectfully submitted,

By:



Byron V. Olsen, Reg. No. 42,960  
Attorney for Applicants  
GTC Biotherapeutics, Inc.  
175 Crossing Blvd., Suite 410  
Framingham, MA 01702  
Tel. #(508) 370-5150  
Fax #(508) 370-3797

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	09/849,657
Filing Date	05/04/2001
First Named Inventor	Harry Meade
Art Unit	1646
Examiner Name	
Attorney Docket Number	GTC-21

Sheet 1 of 2

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 97/466664	12-11-1997	Univ. of Washin		
		WO 99/54491	10-28-1999	Children's Hosp		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 09/849,657

Filing Date 05/04/2001

First Named Inventor Harry Meade

Art Unit 1646

Examiner Name

Attorney Docket Number GTC-21

Sheet

2

of

2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Isaka et al., "Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney", Nature Medicine, Vol 2, pgs. 418-423 (1996)	
		Ko et al., "Production of biologically active human granulocyte colony stimulating factor in the milk of transgenic goat", Transgenic Research, 9: pgs. 215-222 (2000)	
		Moscatello et al., Decorin Suppresses Tomor Cell Growth by Activating the Epidermanl Growth Factor Receptor", J. Clin. Invest., Vol 101, pgs. 406-412 (1998)	
		Ruoslahti, E., "Structure and Bilogy of Proteoglycans", Ann. Rep. Cell Biol., 4, pgs. 229-255 (1988)	
		Stromqvist et al., "Recombinant human bile salt-stimulated lipase: an example of defective O-glycoslyation of a protein produced in milk of transgenic mice", Transgenic Research, 5, pgs. 475-485 (1996)	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.